High-risk MDS and very high-risk MDS are classifications used to describe the severity and prognosis of the disease. These classifications are based on the percentage of abnormal cells in the bone marrow, the type of genetic mutations present, and how many types of blood cells are affected.
Both high-risk and very high-risk MDS require close monitoring and may require aggressive treatment options, such as chemotherapy, bone marrow transplantation, or other targeted therapies, depending on the patient's overall health and individual disease characteristics.
High-risk MDS refers to a high percentage of abnormal cells in the bone marrow (usually 20% or more) and/or distinctive genetic abnormalities. High-risk MDS is generally associated with a poor prognosis and a higher probability of progressing to acute myeloid leukemia (AML), a more aggressive form of blood cancer.
Very high-risk MDS is a more severe form of the disease characterized by a higher percentage of abnormal cells in the bone marrow (usually 30% or more) and/or multiple cytogenetic abnormalities. Very high-risk MDS is associated with a higher likelihood of disease progression to AML and a poorer prognosis compared to high-risk MDS.
There are many different types of MDS. Specialists typically evaluate the bone marrow and the blood cells to determine which type of MDS a person has.
Physicians also use a scoring system called the Revised International Prognostic Scoring System (IPSS-R) to place MDS patients into 1of 5 different risk groups. The 5 risk groups include “very low risk,” “low risk,” “intermediate risk,” “high risk,” and “very high risk.”
MDS specialists and patient advocates emphasize the importance of MDS patients learning their risk category. Those who are in the higher-risk categories (“intermediate risk,” “high risk,” and “very high risk”) may require different types of treatments compared with those with “lower-risk” MDS.
The specific mutations associated with high-risk and very high-risk MDS can vary among individuals, and not all cases of MDS may have identifiable mutations. However, certain genetic mutations are commonly associated with high-risk and very high-risk MDS. Some examples include:
It's important to note that these mutations alone do not definitively determine the risk category or prognosis of MDS, as other factors such as age, overall health status, and response to treatment also play important roles. After the proper tests and questions, an MDS specialist will be able to determine your risk stage and create a personalized treatment plan.
Being your best self-advocate can involve effective communication with your MDS specialist, tracking your MDS, and participating in the decision-making process of your treatment.
By securely connecting your electronic health records, HealthTree Cure Hub allows you to use the clinical trial finder, find a specialist, keep track of your disease, and so much more! Sign up for a free account today to get started.
Source:
High-risk MDS and very high-risk MDS are classifications used to describe the severity and prognosis of the disease. These classifications are based on the percentage of abnormal cells in the bone marrow, the type of genetic mutations present, and how many types of blood cells are affected.
Both high-risk and very high-risk MDS require close monitoring and may require aggressive treatment options, such as chemotherapy, bone marrow transplantation, or other targeted therapies, depending on the patient's overall health and individual disease characteristics.
High-risk MDS refers to a high percentage of abnormal cells in the bone marrow (usually 20% or more) and/or distinctive genetic abnormalities. High-risk MDS is generally associated with a poor prognosis and a higher probability of progressing to acute myeloid leukemia (AML), a more aggressive form of blood cancer.
Very high-risk MDS is a more severe form of the disease characterized by a higher percentage of abnormal cells in the bone marrow (usually 30% or more) and/or multiple cytogenetic abnormalities. Very high-risk MDS is associated with a higher likelihood of disease progression to AML and a poorer prognosis compared to high-risk MDS.
There are many different types of MDS. Specialists typically evaluate the bone marrow and the blood cells to determine which type of MDS a person has.
Physicians also use a scoring system called the Revised International Prognostic Scoring System (IPSS-R) to place MDS patients into 1of 5 different risk groups. The 5 risk groups include “very low risk,” “low risk,” “intermediate risk,” “high risk,” and “very high risk.”
MDS specialists and patient advocates emphasize the importance of MDS patients learning their risk category. Those who are in the higher-risk categories (“intermediate risk,” “high risk,” and “very high risk”) may require different types of treatments compared with those with “lower-risk” MDS.
The specific mutations associated with high-risk and very high-risk MDS can vary among individuals, and not all cases of MDS may have identifiable mutations. However, certain genetic mutations are commonly associated with high-risk and very high-risk MDS. Some examples include:
It's important to note that these mutations alone do not definitively determine the risk category or prognosis of MDS, as other factors such as age, overall health status, and response to treatment also play important roles. After the proper tests and questions, an MDS specialist will be able to determine your risk stage and create a personalized treatment plan.
Being your best self-advocate can involve effective communication with your MDS specialist, tracking your MDS, and participating in the decision-making process of your treatment.
By securely connecting your electronic health records, HealthTree Cure Hub allows you to use the clinical trial finder, find a specialist, keep track of your disease, and so much more! Sign up for a free account today to get started.
Source:
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.